Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERU: Rovalpituzumab Tesirine Maintenance in SCLC
NCT03033511Phase 3Terminated
- Sponsor
- AbbVie Inc.
- Start
- Feb 2017
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 41
01
Overview
A Phase 3 trial of rovalpituzumab tesirine in small cell lung cancer (SCLC), sponsored by AbbVie Inc.. Started Feb 2017; status: terminated.
02
Drugs
rovalpituzumab tesirine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03033511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03033511.